Mycobacterium tuberculosis (Mtb) PE PGRS33 is a surface-exposed protein that was shown to interact with Toll-like receptor 2 on host macrophages to induce inflammatory signals and promote entry in macrophages. In this study, we investigated PE PGRS33 as a potential target of a humoral response aimed at hampering key processes in tuberculosis pathogenesis. PE PGRS33 protein was successfully expressed and purified under native condition in Escherichia coli. The purified protein retained its native functional and biological properties, showing the ability to elicit proinflammatory signals in murine and human macrophages. Interestingly, a polyclonal antiserum raised against native PE PGRS33 showed no cross-reactions with other mycobacterial proteins. The anti-PE PGRS33 serum was also able to inhibit Mtb entry into macrophages, but it did not reduce entry of the Mtb pe pgrs33 strain. Addition of native recombinant PE PGRS33 to the Mtb pe pgrs33 strain during infection restored the Mtb wild-type entry phenotype in macrophage. Moreover, the anti-PE PGRS33 serum was able to neutralize the proinflammatory activity of PE PGRS33 in vitro. Furthermore, mice immunized with native recombinant PE PGRS33, but not with a DNA vaccine expressing PE PGRS33, were able to restrict M. smegmatis in vivo. These results highlight the potential use of PE PGRS33 as a target of a neutralizing humoral response against tuberculosis.
INTRODUCTION
Tuberculosis (TB) is one of the major infectious diseases responsible for high mortality and morbidity worldwide (World Health Organization 2016) . The increasing number of HIV-associated cases and the spread of multidrug-resistant and extensivelyresistant Mycobacterium tuberculosis (Mtb) strains are making the situation even worse (Podlekareva et al. 2016) . There is an urgent need of new tools to control the TB epidemic and a new and improved vaccine would have a significant impact at global level (Delogu, Manganelli and Brennan 2014) . In the last 20 years, several different technologies have been used to develop new immunization strategies against TB and promising preclinical data were obtained for many new vaccines, with the most promising already entering clinical trials (Delogu, Manganelli and Brennan 2014) . Unfortunately, the results of the first phase 2b trial carried out in children cooled the many expectations (Tameris et al. 2013) , highlighting the complexity behind the development of an improved vaccine against TB and the need of new and outof-the-box approaches to tackle this issue. These may include research aimed at testing the possibility that humoral immune response can provide protection against Mtb infection and or disease (Achkar and Casadevall 2013; Delogu et al. 2015) .
Protective humoral-based immunity is usually achieved by targeting surface proteins or molecules known to be directly involved in host-pathogen interaction. Unfortunately, we have an insufficient understanding of the mycobacterial surface molecular organization and of the proteins available for interaction with host components. Proteins belonging to the PE PGRS family are surface available proteins present in multiple copies in Mtb, where these are thought to play a key role in the interaction with the host Banu et al. 2002; Delogu, Cole and Brosch 2008; Iantomasi et al. 2012; Ahmed, Das and Mukhopadhyay 2015; Fishbein et al. 2015; Palucci et al. 2016) .
PE PGRS33 is among the most studied protein of the family. It is a 498-amino-acid long protein containing 21 GGA/X repeats in the polymorphic PGRS domain (Brennan and Delogu 2002) . Its PE domain is responsible for protein translocation on the mycobacterial outer membrane so that the PGRS domain is exposed to the extracellular side (Delogu et al. 2004; Cascioferro et al. 2007) , where it is available to interact with host components. It has been demonstrated that PE PGRS33 plays immunomodulatory activities by directly interacting with Tolllike receptor (TLR2), which triggers the secretion of a number of chemokines and cytokines, including TNFα (Basu et al. 2007; Zumbo et al. 2013) . PE PGRS33-mediated immunomodulatory properties were shown to depend on the PGRS domain (Dheenadhayalan, Delogu and Brennan 2006; Basu et al. 2007; Zumbo et al. 2013) . Recently, we have generated and characterized an Mtb H37Rv null mutant for PE PGRS33 (Mtb 33), demonstrating that PE PGRS33 mediates Mtb entry in macrophages through interaction with TLR2 (Palucci et al. 2016) . Hence, we consider PE PGRS33 as a natural candidate to assess whether humoral responses can exert a protective effect against Mtb infections, testing its potential use as target of a neutralizing humoral response.
MATERIAL AND METHODS

Construction of 6xHis-SUMO fusion expression vector and expression in Escherichia coli
Rv1818c gene, encoding PE PGRS33 protein, was amplified from Mtb H37Rv strain DNA by PCR, using primers 1818c5ATG (5 -ATGTCATTTGTGGTCACGATC-3 ) and 1818c3STOP (5 -CTACGGTAACCCGTTCATCCC-3 ), and ligated into pET-SUMO vector (Life Technologies). The recombinant construct whose sequence was confirmed by automated DNA sequencing, was named rPE PGRS33. It was transformed into E. coli BL21 (DE3) chemically competent cells (Life Technologies, Carlsbad, California) , and a single positive colony was inoculated in 10 ml of LB broth with 50 μg/ml kanamycin, 1% glucose and grown overnight (o.n.) at 37
• C in shaking. LB broth (250 ml), enriched as before, were subinoculated with 2.5 ml of the previously grown culture. The culture was incubated at 37 • C until a 0.6 O.D. 600nm was reached and then it was centrifuged at 14 000 rcf for 20 min at 4 • C. Pellet was resuspended in 250 ml of LB broth with 50 μg/ml kanamycin and induced by adding 1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) for 3 h.
Protein purification
Induced culture was pelleted (14 000 rcf for 15 min at 4
• C) and lysed in 25 ml of lysis buffer (pH = 8, 20 mM Tris-HCl, 200 mM NaCl, 100 μg/ml lysozyma, 1:200 protease inhibitor, 0.02% sodium azide) by sonication (five times for 1 min in ice) and freeze-thawed cycles (three times). Supernatant was separated from bacterial cells by centrifugation (14 000 rcf, for 15 min at 4
• C) and collected for purification. Soluble lysate containing 6XHis-tagged rPE PGRS33 was purified by ion metal affinity chromatography with Ni-NTA agarose 5 ml bed volume column (GEHealth Care, Little Chalfont, UK) in Fast Protein Liquid Chromatography (FPLC). The column was equilibrated with three bed volumes of buffer A (pH = 8, containing 20 mMTris-HCl, 200 mM NaCl, 0.02% sodium azide). Buffer B, similar to buffer A and supplemented with 500 mM imidazole, was used mixed with buffer A in order to have an increasing linear gradient of imidazole (from 50 to 350 mM) for washing out the non-specifically bound proteins, while rPE PGRS33 was eluted with 500 mM imidazole. Eluted fractions were collected and analyzed by SDS PAGE. The fraction containing rPE PGRS33 was dialyzed for 24 h against phosphate-buffered saline (PBS) to remove salt, detoxified (removing LPS) and concentrated. 
SDS-PAGE, western blotting and immunoblotting
Cell lines culture
J774 (ATCC) murine macrophages and human THP-1 monocytic cells were grown as previously described (Palucci et al. 2016) . THP1-XBlue reporter cells (InvivoGen, San Diego, California) were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 1 mM sodium pyruvate, 100 μg/ml streptomycin, penicillin and zeocin and were kept in a humidified atmosphere containing 5% CO 2 at 37 • C. Cells were treated with 20 nM PMA (Sigma-Aldrich, St. Louis, MO) for 48 h to induce their differentiation into macrophage-like cells, and then washed three times with PBS and maintained in complete medium with 5% FCS.
Mycobacterial infection and bacterial counts in vitro
J774 murine macrophages were plated at 1.2 × 10 6 per ml in 48-well plate, infected with Mtb H37Rv and Mtb 33 strains at multiplicity of infection (MOI) of 1:10 for 1 h and incubated in a 5% CO 2 atmosphere at 37 • C. Once infecting solutions were removed, cells were washed three times with PBS and incubated with maintaining medium (complete RPMI, 2% FCS, without antibiotics). At 4 h post infection (p.i.), cells were washed three times with PBS to remove extracellular bacteria, lysed in 0.01% Triton X-100 and intracellular bacteria determined by colony forming units (CFUs) counting by serially diluting lysates in PBS containing 0.05% Tween80 and plating on 7H11/OADC agar plates (Palucci et al. 2016) . Colony counting was performed in triplicate. When used in coinfection with Mtb 33, rPE PGRS33 was added at 0.1 or 0.05 μg/ml. When anti-PE PGRS33 and preimmune sera were used, these were incubated with Mtb H37Rv or Mtb 33 at different dilutions (1:200, 1:400) since 30 min before infection at 37
• C in shacking.
THP-1 monocytic cells were plated at 1.2 × 10 6 per ml in 48-well plate, infected with opsonized and non-opsonized MtbH37Rv and Mtb 33 (MOI 1:10) for 2 h, and incubated in a 5% CO 2 atmosphere at 37 • C. Bacilli opsonization was carried out as described in Klink et al. (2013) . Intracellular CFUs were counted at 4 h p.i., as indicated above for J774.
Measurement of PE PGRS33-mediated NF-κB/AP-1 pathway activation and TNF-α production
THP1-XBlue and J774 cells were plated at 1.2 × 10 6 per ml in 96-well and 48-well plates, respectively. Cells were infected using recombinant strains of M. smegmatis (Ms vector: Ms expressing empty vector; Ms H PE PGRS33: Ms expressing PE PGRS33 protein under hsp60 promoter) (Delogu et al. 2004; Dheenadhayalan, Delogu and Brennan 2006 ) (MOI 5:1) and the purified rPE PGRS33 protein (1 μg/ml) and incubated for 4 h at 37
• C in a 5% CO 2 atmosphere. All the infections were also performed in the presence of anti-PE PGRS33 serum, diluted at 1:200 and pre-incubated with the infecting solutions as before. At 4 h p.i., cells were washed three times with PBS and incubated with maintaining medium. For THP1-XBlue cells, QUANTI-Blue medium (InvivoGen) was added to the supernatants 24 h p.i. and, after 15 min to 24 h of incubation, secreted embryonic alkaline phosphatase activity was assessed by reading the O.D.at 630 nm with a microplate reader (BioRad). For J774 cells, culture supernatants at 24 h p.i. were assayed for TNF-α production by ELISA, using the murine Biotrak TNF-α assay kit (BD Biosciences, San Jose, California) and according to the manufacturer's protocol.
Mice immunization and in vivo infection
Pathogen-free female Balb/c mice were obtained from the Università Cattolica del Sacro Cuore (Rome) and housed in a temperature-controlled environment with 12 h light/dark cycles, and received food and water ad libitum. Groups of animals, 4-8 weeks old, were injected subcutaneously in two sites at the base of the tail with 100 μl of purified rPE PGRS33 protein emulsified with TiterMax Gold Adjuvant (Sigma-Aldrich) at a final concentration of 125 μg/ml. A second group of mice was immunized intramuscularly with 100 μg of 1818 PE PGRS DNA vaccine . Immunization was repeated three times, 15 days apart, and sera were collected 2 weeks after the third immunization by the tail vein (De Maio et al. 2014) . Three weeks after the third immunization, immunized and control mice were infected by intraperitoneal injection with 2 × 10 7 CFUs per ml of Ms H PE PGRS33 (Zumbo et al. 2013) ; as a further control, nonimmunized mice were also infected with the parental M. smegmatis strain (Ms) (Zumbo et al. 2013) . At day 10 p.i., mice were sacrificed and spleens removed to assess bacterial burden by CFU counting. All manipulations were performed under isoflurane anesthesia, and all efforts were made to minimize suffering. All animal experiments were authorized by the Ethical Committee of the Università Cattolica del Sacro Cuore, Rome (Prot. n 
Statistical analysis
All the experiments were performed at least in triplicate and replicated at least three times. GraphPad Prism software version 6.0 (GraphPad, CA, USA) was used for statistical analysis.
All the data were expressed as mean with SD and analyzed by one-way or two-way ANOVA followed by Tukey's multiple comparison test, as specified in the captions under each figure.
RESULTS
PE PGRS33 in its native form induces specific antiserum
To investigate the potential of PE PGRS33 as a candidate target for an effective humoral response, we first developed a system to purify the protein in its native form. A number of attempts were made to express and purify the histidine-tagged protein in Escherichia coli and Mycobacterium smegmatis using different systems without success. In fact, even though protein expression could be achieved, the amount that we were able to purify in native form was extremely low (data not shown). However, expression of PE PGRS33 as a fusion with SUMO in E. coli led to the purification of a significant amount of protein under nondenaturing conditions (Fig. 1A and B) . Immunization of Balb/c mice with the purified rPE PGRS33 resulted in the generation of an antiserum, whose specificity was evaluated by immunoblot on BCG (Fig. 1C) and E. coli lysates (data not shown). Anti-PE PGRS33 serum recognized a band at the expected MW of ≈45 kDa in the whole cell lysate obtained from the recombinant BCG strain transformed with the multicopy pMV206-derived plasmid, where expression of PE PGRS33 is under the control of the putative pe pgrs33 promoter (Cascioferro et al. 2011) . Conversely, we could not detect a band at the expected MW of PE PGRS33 in the lysate of the BCG parental strain, and no other band was detected by the anti-PE PGRS33 in the cell lysates of BCG (Fig. 1C) or Mtb (data not shown). When the PE PGRS33 antiserum was used at higher concentrations, nonspecific bands were detected, as assessed including a M. smegmatis cell lysate as a control (data not shown). Moreover, the anti-PE PGRS33 correctly detected the band at the expected MW in the recombinant E. coli lysates expressing rPE PGRS33 following IPTG induction but not in the lysate obtained when the same E. coli strain was not induced with IPTG (data not shown). Together, these results suggest that the polyclonal anti-PE PGRS33 serum is specific for PE PGRS33. 
PE PGRS33 triggers a proinflammatory pathway that is neutralized by an anti-PE PGRS33 antiserum
With the objective to assess whether native PE PGRS33 retained its immunomodulatory activity, we employed a cellular model monitoring TLR-induced NF-κB/AP-1 pathway activation (Knopick and Bradley 2017) . THP1-XBlue cells were incubated with rPE PGRS33 and, as positive and negative controls, cells were infected with recombinant M. smegmatis strains expressing or not PE PGRS33 (Ms H PE PGRS33 and Ms vector). As shown in Fig. 2A , heterologous expression of PE PGRS33 in M. smegmatis and purified rPE PGRS33 were able to activate the NF-κB/AP-1 pathway at higher levels compared to the M. smegmatis parental strain. Anti-PE PGRS33 serum was able to neutralize the PE PGRS33-mediated NF-κB/AP-1 activation pathway following stimulation with rPE PGRS33 and Ms H PE PGRS33, while it had no effect on cells infected with the Ms vector. Moreover, purified rPE PGRS33 was capable of inducing TNF-α secretion from murine macrophages and, once more, the anti-PE PGRS33 serum was able to neutralize the PE PGRS33-mediated TNF-α secretion following stimulation with rPE PGRS33 or infection with the M. smegmatis expressing PE PGRS33 (Fig. 2B) . These results indicate that native rPE PGRS33 retained the same immunomodulatory properties of the protein expressed in mycobacteria (Zumbo et al. 2013) and that the anti-PE PGRS33 serum specifically interfered with the activity of the protein.
Native PE PGRS33 added to Mtb 33 strain restores Mtb wild-type entry phenotype
We have recently shown that PE PGRS33-mediated entry of Mtb in macrophages depends on the ability of PE PGRS33 to bind to TLR2, which by activating the inside-out signaling, enhances the avidity of CR3 for mycobacteria (Palucci et al. 2016) . Here, we investigated whether rPE PGRS33 protein in its native form and coadministered with the Mtb 33 strain is capable of restoring the wild-type entry phenotype. Murine macrophages (J774) were infected with Mtb H37Rv and the Mtb 33 alone or in the presence of rPE PGRS33. As shown in Fig. 3 , adding rPE PGRS33 at concentrations of 0.1 or 0.05 μg/ml to the cells infected with Mtb 33 restored the wild-type entry phenotype (P < 0.01). These results suggest that rPE PGRS33 retains the ability to bind TLR2 and activate the intracellular signal that mediates the PE PGRS33-dependent entry of Mtb in macrophages.
Mtb PE PGRS33-mediated entry in macrophages is neutralized by anti-PE PGRS33 antibodies and is opsonization independent
Following our findings that PE PGRS33 mediates Mtb entry in macrophages (Palucci et al. 2016) , we aimed to test whether our specific anti-PE PGRS33 serum could inhibit this function by specifically interfering with the protein expressed on the bacilli surface. As shown in Fig. 4A , Mtb H37Rv entry in macrophages was impaired when anti-PE PGRS33 serum was included during infection. Conversely, addition of pre-immune serum, used as a control, did not affect the Mtb wild-type entry phenotype, suggesting that the observed anti-PE PGRS33 serum activity was not related to any other serum component. To further assess the specificity of the anti-PE PGRS33 serum activity, the same amount of serum was incubated with the Mtb 33 strain and no differences were observed in the efficiency of macrophage infection between treated and untreated groups (Fig. 4B) . Moreover, no differences were observed when we measured the efficiency to infect macrophages of opsonized, non-opsonized Mtb wild type or Mtb 33 (Fig. 4C) , indicating that PE PGRS33-mediated entry of Mtb in macrophages occurs independently on the opsonization and through the activation of the TLR2-dependent proadhesive pathway (Palucci et al. 2016) .
These results demonstrated that the anti-PE PGRS33 serum raised against native rPE PGRS33 was able to reduce the PE PGRS33-dependent ability of Mtb to entry in macrophages.
The enhanced virulence in vivo of Mycobacterium smegmatis expressing PE PGRS33 is neutralized in mice immunized with native recombinant PE PGRS33
To investigate the biological role of anti-PE PGRS33 serum in vivo, Balb/c mice immunized with native rPE PGRS33 protein or with a DNA vaccine expressing full-length PE PGRS33 and control non-immunized mice (n.i.) were infected by the intraperitoneal route with Ms H PE PGRS33 (Dheenadhayalan, Delogu and Brennan 2006 μg/ml and * * P < 0.01 Mtb 33 vs Mtb 33 + rPE PGRS33 added at 0.1 μg/ml (one-way ANOVA, Tukey's multiple comparison test). Zumbo et al. 2013) , Ms H PE PGRS33 showed enhanced persistence in spleen tissue of Balb/c mice compared to the Ms vector (Fig. 5) . Interestingly, we found that mice immunized with rPE PGRS33 protein restrained Ms H PE PGRS33 infection, showing halved bacterial load in the spleen compared to non-immunized mice (Fig. 5) . Conversely, mice immunized with the DNA vaccine did not significantly contain Ms H PE PGRS33 infection. These results suggest that antibodies elicited following immunization with purified native rPE PGRS33 protein, but not DNA vaccine expressing PE PGRS33, were able to partially impair PE PGRS33-dependent biological and immunomodulatory activities in vivo, as demonstrated in our M. smegmatis model of infection. 
DISCUSSION
PE PGRSs are a large family of surface-exposed proteins that are found in MTB complex and few other pathogenic mycobacteria as Mycobacterium ulcerans and M. marinum (Delogu, Cole and Brosch 2008; Fishbein et al. 2015) . In this study, we aimed to investigate whether targeting the well-characterized PE PGRS33 protein by a specific antiserum could result in the neutralization of the protein biological activities. The results obtained indicate that anti-PE PGRS33 antibodies can interfere with the protein ability to promote Mtb entry in macrophages and trigger proinflammatory signals, both of which are dependent on the binding of PE PGRS33 to TLR2. These results support the hypothesis that targeting certain mycobacterial surface proteins with specific antibodies could be seen as a strategy to control Mtb replication.
The difficulties in purifying PE PGRS33, as well as other PE PGRSs, in native conditions hampered for long time an appropriate biological characterization of these proteins and the development of a specific antiserum capable of targeting a natively folded protein. We developed a number of expression systems in Escherichia coli and mycobacteria, before succeeding in purifying sufficient amounts of PE PGRS33 under native conditions. Using the pET-SUMO expression system in E. coli followed by purification by affinity chromatography (FPLC), we were able to obtain purified PE PGRS33 protein. Although the yield of the purified protein was relatively low (0.5 mg/l of culture), the purity was high and suitable to test the protein in a number of assays and to immunize mice.
The purified rPE PGRS33 protein obtained in E. coli maintained its biological activity, suggesting that it retained the (Brennan and Delogu 2002) or with the recombinant PE PGRS33 purified from E. coli, administered with the adjuvant TiterMax. Mice were immunized three times, two weeks apart, and three weeks after the third vaccination mice were infected i.p. with M. smegmatis parental strain and M. smegmatis overexpressing PE PGRS33. Ten days after infection, mice were sacrificed, spleens removed and bacterial load assessed by CFUs counting. proper folding required for interaction with host receptors. It is likely that the presence of SUMO at N-terminus provides the stability necessary for the protein to remain in solution. The possibility to obtain sufficient amounts of PE PGRS33 in the native form could open the possibility for its biophysical characterization, which could shed light on the whole protein structure, including the domains rich in GGA/GGX repeats and to identify the domain(s) involved in the interaction with TLR2. Moreover, the same expression system would be useful also to purify other PE PGRS proteins. In previous studies, sera obtained from mice immunized with a DNA vaccine encoding full-length PE PGRS33 (1818 PE PGRS )
showed cross-reactivity with other PE PGRS proteins ) and the monoclonal antibody mAb 7C4.1F7, obtained from mice immunized with the purified denatured protein obtained in E. coli, did react with a number of proteins in Mtb whole cell lysates (Abdallah et al. 2009 ). On the contrary, here we show that the PE PGRS33 purified under native conditions elicits a highly specific antiserum that apparently does not cross react with any other PE PGRSs in the BCG lysate (Fig. 1C) . It remains to be seen why the antiserum raised with the native protein behaves differently from the anti-serum raised with a DNA vaccine or the monoclonal antibody, but it is possible that certain structural epitopes could be properly exposed only following immunization with the native protein. Interestingly, the antiserum raised against the native protein was capable of specifically inhibiting PE PGRS33-mediated Mtb entry into macrophages (Fig. 4B ) and neutralized the immunomodulatory properties of the protein when administered in the purified form or expressed in the heterologous form in M. smegmatis ( Fig. 2A and B) . Moreover, the anti-PE PGRS33 humoral response induced by immunizing mice with native PE PGRS33, but not with 1818 PE PGRS DNA vaccine, interfered with the pathogenic features associated with the infection of mice with M. smegmatis expressing H PE PGRS33 (Dheenadhayalan, Delogu and Brennan 2006; Zumbo et al. 2013) (Fig. 5) , suggesting that inhibition of the proinflammatory activities of PE PGRS33 may impact the course of Mtb infection (Camassa et al. 2017) . Future studies will be useful to investigate the role of anti-PE PGRS33 antibodies recognizing the native protein during Mtb in relevant in vivo models of infection.
The results of this study further highlight the need to identify Mtb surface proteins with a well-characterized biological activity that can be specifically targeted by innovative prophylactic or immunotherapeutic regimens (Delogu et al. 2015; Zanetti et al. 2005) . Vaccination strategies targeting proteins with immunomodulatory properties may impact on TB pathogenesis by limiting tissue damage and reducing risk of transmission (Achkar and Casadevall 2013; Delogu et al. 2015) . Given the many difficulties associated with the development of a new vaccine against TB (Delogu et al. 2015) , there is a need to identify new and out-of-the-box approaches, including a reconsideration of the potential protective role for humoral response. Characterization of the neutralizing activity of antibodies directed against surface proteins such as PE PGRS33 may represent an opportunity to assess the potential role of the humoral response against TB.
